Phase 2, open-label INSPIRE trial to assess the tolerability and effectiveness of transdermal cannabidiol gel in children and adolescents with 22q11.2 deletion syndrome (ZYN2-CL-031).

A phase 2 open-label trial evaluated transdermal CBD for 22q11.2 deletion syndrome in children, demonstrating tolerability with preliminary behavioral improvements. While promising for this rare genetic condition, controlled trials are needed to establish definitive therapeutic benefits before clinical implementation.

Read More